Announcements

Announcements

 
Gavi [to 13 January 2018]
http://www.gavi.org/library/news/press-releases/
09 January 2018
Cyrus Ardalan becomes new Chair of IFFIm Board
Ardalan succeeds René Karsenti, who oversaw nearly US$ 2.5 billion in bond issuances, entry into Sukuk markets.
 
 
GHIT Fund   [to 13 January 2018]
https://www.ghitfund.org/
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical ·
2018.01.10    News
Announcement of New Board Member
The GHIT Fund today announced that Mr. Daikichi Momma, Special Researcher at the Policy Research Institute, Ministry of Finance, and Former Director-General of the International Bureau, Ministry of Finance, has been appointed as a new member of the Board of Directors of the GHIT Fund.
 
 
Hilleman Laboratories   [to 13 January 2018]
http://www.hillemanlabs.org/
Date: 09/01/2018
Hilleman Laboratories partners with innovative Future Vaccine Manufacturing
Hilleman Laboratories, an equal joint-venture partnership between MSD and Wellcome Trust, is honored to be one of the key partners of the new Future Vaccine Manufacturing Hub led by Imperial College London. The hub has been established to increase immunisation coverage across the globe and improve the response to disease outbreaks through the rapid and cost-effective deployment of vaccines. £10 million of funding has been granted by the UK Department for Health, and will be managed by the Engineering and Physical Sciences Research Council (EPSRC)…
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
09 January 2018
Cyrus Ardalan becomes new Chair of IFFIm Board
Ardalan succeeds René Karsenti, who oversaw nearly US$ 2.5 billion in bond issuances, entry into Sukuk markets.

IVAC  [to 13 January 2018]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
January 9, 2018
5 Reasons the Global Gap in Rotavirus Vaccine Access is Shrinking
This article was originally posted on the Impatient Optimists Blog on January 9, 2018.
45 million children have access today, millions more expected to gain access to vaccine in 2018
 
 
IVI   [to 13 January 2018]
http://www.ivi.int/
January 8, 2018
Euvichol-Plus®, ‘the world’s first plastic vial oral cholera vaccine,’ ready for global use
:: First shipment of new OCV from EuBiologics in South Korea to Zambia and Somalia from January 5 follows WHO approval in August 2017
:: Innovative packaging makes vaccine more affordable and easier to use
:: Up to 50 million doses in production to supply the global market
:: Developed by global public-private partnership to advance vaccines for global public health
SEOUL, January 8, 2018 — ‘Euvichol-Plus®’, the world’s first oral cholera vaccine (OCV) presented in plastic tube vials, is now available for purchase by international procurement agencies and United Nations (UN) agencies following the first shipment of 2.45 million doses to Zambia and Somalia from January 5. The vaccine, produced by EuBiologics, a South Korean pharmaceutical company, was prequalified by the World Health Organization (WHO) in August 2017.
Euvichol-Plus® is a low-cost oral cholera vaccine presented in innovative plastic packaging, and is an improved version of Euvichol®, an OCV presented in glass vials also produced by EuBiologics and WHO-approved in 2015. The new plastic packaging reduces the vial’s volume by nearly 30 percent and weight by over 50 percent, allowing easier transport and distribution of the vaccine and waste management. Compared with conventional glass vials, the plastic packaging is easier to open and administer.
Notably, Euvichol-Plus, priced at about $1.30 per dose, is 25 percent cheaper than Euvichol, which will enable aid and vaccine delivery organizations to procure more vaccines at the same cost. If Euvichol-Plus had existed just one year ago – and had been shipped in place of Euvichol – more than US $2.3 million would have been saved. These cost savings could have been used to purchase nearly 1.8 million more doses of Euvichol-Plus…
 
 
MSF/Médecins Sans Frontières  [to 13 January 2018]
http://www.doctorswithoutborders.org/news-stories/press/press-releases
Press release
Syria: Demining Urgently Needed in Raqqa as MSF Treats 33 Blast Victims in One Week
RAQQA, SYRIA/AMSTERDAM/NEW YORK, JANUARY 12, 2018—Teams from Doctors Without Borders/ Médecins Sans Frontières (MSF) treated 33 patients with blast injuries in Raqqa city, Syria, during the first week of 2018, underlining the urgent need for demining in and around the war-torn city.

Press release
MSF: End of Temporary Protected Status for Salvadorans Puts Lives at Risk
January 08, 2018
The decision by the Trump Administration to end Temporary Protected Status (TPS) for approximately 200,000 Salvadorans living in the US threatens to directly endanger their lives, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) said today
 
 
NIH  [to 13 January 2018]
http://www.nih.gov/news-events/news-releases
January 12, 2018
The coming of age of gene therapy: A review of the past and path forward
— No longer the future of medicine, gene therapy is part of present-day clinical treatment.
After three decades of hopes tempered by setbacks, gene therapy—the process of treating a disease by modifying a person’s DNA—is no longer the future of medicine, but is part of the present-day clinical treatment toolkit. The Jan. 12 issue of the journal Science provides an in-depth and timely review of the key developments that have led to several successful gene therapy treatments for patients with serious medical conditions.

January 11, 2018
NIH study supports use of short-term HIV treatment interruption in clinical trials
— Findings may aid design of trials to assess strategies to control HIV without drugs.
 
 
PATH  [to 13 January 2018]
http://www.path.org/news/index.php
Press release | January 08, 2018
PATH names Elaine Gibbons vice president for Global Engagement and Communications
Global leader combines more than 15 years of experience with multisector partnerships, marketing and strategy with a demonstrated passion for human rights and international development

Sabin Vaccine Institute  [to 13 January 2018]
http://www.sabin.org/updates/pressreleases
January 8, 2018
Sabin to tackle pandemic flu
WASHINGTON, D.C. –The Sabin Vaccine Institute, a non-profit global health organization dedicated to enabling vaccine innovation, making vaccines more accessible and expanding immunization across the globe, is pleased to announce a new three-year $6.6 million grant to help speed the development of next generation influenza vaccines and support related immunization issues. This work is generously supported by the Page Family Donor Advised Fund.
 

UNAIDS [to 13 January 2018]
http://www.unaids.org/en
12 January 2018
UNAIDS and Australia strengthen ties to end AIDS

12 January 2018
UNAIDS mourns the death of Jimmie Earl Perry
Jimmie Earl Perry, the first UNAIDS National Goodwill Ambassador for South Africa, has died.

10 January 2018
UN urges comprehensive approach to sexuality education
Close to 10 years after its first edition, a fully updated International Technical Guidance on Sexuality Education published today by UNESCO advocates quality comprehensive sexuality education to promote health and well-being, respect for human rights and gender equality, and empowers children and young people to lead healthy, safe and productive lives…

UNICEF  [to 13 January 2018]
https://www.unicef.org/media/
9 January 2018
Geneva Palais Briefing Note: The situation of children in Rakhine State, Myanmar
GENEVA, 9 January 2018 – This is a summary of what was said by Marixie Mercado, UNICEF spokesperson in Geneva – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva.

Wellcome Trust  [to 13 January 2018]
https://wellcome.ac.uk/news
News / Published: 10 January 2018
Investing in medical research yields healthy returns
Every £1 invested in medical research delivers a return equivalent to 25p every year, a new study shows.
Through taxes and donations, the government, charities and the public invest significant sums of money into medical research. The peer-reviewed ‘What’s it worth?’ study shows that this investment delivers outstanding benefits for the economy, as well as for people’s health.

::::::
 
BIO    [to 13 January 2018]
https://www.bio.org/insights/press-release
Jan 9 2018
BIO Applauds Support for Innovation in Trump Administration Task Force Report
 “Biotechnology Sector is a Driver of the ‘Fourth Industrial Revolution’”
Washington, D.C. (January 9, 2018) – The Biotechnology Innovation Organization (BIO) is applauding a new report from the Interagency Task Force on Agriculture and Rural Prosperity, which encourages growth and continued innovation in America’s biotechnology sector…
:: Report pdf: https://www.usda.gov/sites/default/files/documents/rural-prosperity-report.pdf

 
PhRMA    [to 13 January 2018]
http://www.phrma.org/press-room
January 12, 2018
ICYMI: Why 2017 medicine approvals matter
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary milestone for the biopharmaceutical industry and the FDA with major medicine approvals. According to the report, the FDA approved 46 new molecular entities for a range of disease states — the highest number of new medications in 21 years.
Of the 46 new medicines, 15 are first in class treatments, including the first treatment approved for the primary progressive form of multiple sclerosis and a medicine that provides an entirely new way of treating severe eczema. The agency also approved 10 biological therapeutics through the Center for Biologics Evaluation and Research.
Other notable approved medicines include a treatment for Parkinson’s, the first in more than 10 years, along with the first drug for the treatment of patients with ALS in 22 years. Cancer treatment also made great strides in 2017, with the approval of 16 oncology medications. And significantly, a new era of cell and regenerative medicine brought the approval of the first gene therapies

Industry Watch   [to 13 January 2018]
:: GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older
Jan 12, 2018, – QUADRIVALENT (Influenza Vaccine) to include use in persons 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older.